NCT02711852 2023-09-11
A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)
SecuraBio
Phase 2 Completed
Clinical Trials
3 trialsNCT01476657 2021-03-17
A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
SecuraBio
Phase 1 Terminated
NCT01871675 2016-07-11
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
SCRI Development Innovations, LLC
Phase 1 Completed